Global specialty pharmaceutical and medication delivery company, Hospira, has launched a new generic in the US market.
The generic in question is a carbapenem antibiotic known as imipenem-cilastatin, and it is designed for use in injections. The branded version of the drug was popularized by Merck under the name Primaxin. In 2010, it brought Merck roughly $140 million worth of revenue.
Read the full article at the Daily Herald.